Exhibition of the Kevorkian collection : including objects excavated under his supervision : exhibited at the galleries of Charles of London ... New York, March-April, 1914.

Cover title: Exhibition of Muhammedan-Persian art.

The Right to Die Debate: The Demonization of Dr. Kevorkian and the Creation of a Moral Panic Surrounding Physician-Assisted Suicide in the United States

The Right to Die Debate is a recent but highly controversial moral matter. In particular, physician-assisted suicide (PAS) is an issue that has been evaded by the medical community for years. As of 1990, most states had never encountered the issue before and therefore did not have any laws in place to prohibit PAS (Strate et. al, 2005). Dr. Jack Kevorkian, a retired pathologist from Royal Oak Michigan was the first to publicly address PAS. He brought the issue into the limelight through a bizarre and crude series of assisted deaths that had a lasting impact on not only the Right to Die Debate as whole, but on public policy and both federal and state governmental agendas. This study focuses on the way in which the media, in particular the New York Times (NYT) has portrayed Dr. Jack Kevorkian as incompetent, morally culpable and in an overall negative light in the past twenty years. Applying Stanley Cohen’s 1972 theory of moral panic, a content analysis of NYT media publications between 1990 and 1999 supports Cohen’s theory and reveals that the media has created a moral panic surrounding Kevorkian. This has in turn led to public policy that prevents both terminally ill individuals and their doctors from having a desirable choice; that of voluntary euthanasia and PAS.

Group of photos of the Kevorkian family, 1922-1938, depicting Jack Kevorkian as a child, his sisters Flora and Margo as children, and their parents.

Group photo of Levon and Satenig Kevorkian (Jack Kevorkian's parents), his sisters Flora and Margo, Jack Kevorkian as a teenager and a child, and Satenig Kevorkian.

Business card "Kevorkian M.E.R.C.Y. Amendment"

Jack Kevorkian's business card. Card has a printed message "Kevorkian M.E.R.C.Y. Amendment. Moment Ensuring the Right to Choose for Yourself." Contact information is indicated on the card.

Jack Kevorkian and Tom Cruise

A photo of Jack Kevorkian and Tom Cruise, taken by a cell phone during the 2010 Emmy Awards ceremony.

Jack Kevorkian and Tom Cruise

Verso of a photo of Jack Kevorkian and Tom Cruise, taken by a cell phone during the 2010 Emmy Awards ceremony.

Jack Kevorkian and Tom Cruise

Photo of Jack Kevorkian and Tom Cruise, taken by a cell phone during the 2010 Emmy Awards ceremony. Poor quality.

Jack Kevorkian and Tom Cruise (verso)

Verso of a photo of Jack Kevorkian and Tom Cruise, taken by a cell phone during the 2010 Emmy Awards ceremony.

Jack Kevorkian and Tom Cruise

Photo of Jack Kevorkian and Tom Cruise, taken by a cell phone during the 2010 Emmy Awards ceremony. Unidentified people in the background. Poor quality.

Jack Kevorkian and Tom Cruise

Verso of a photo of Jack Kevorkian and Tom Cruise, taken by a cell phone during the 2010 Emmy Awards ceremony.

Jack Kevorkian's 2010 Emmy Awards ceremony ticket

2010 Emmy Awards ceremony ticket

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily in chronic-phase (CP) chronic myelogenous leukemia (CML) after imatinib treatment failure. In phase I, responses occurred with once-daily administration despite only intermittent BCR-ABL inhibition. Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose-and schedule-optimization study is reported. Patients and Methods In this open-label phase III trial, 670 patients with imatinib-resistant or -intolerant CP-CML were randomly assigned 1: 1: 1: 1 between four dasatinib treatment groups: 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily. Results With minimum follow-up of 6 months (median treatment duration, 8 months; range, = 1 to 15 months), marked and comparable hematologic (complete, 86% to 92%) and cytogenetic (major, 54% to 59%; complete, 41% to 45%) response rates were observed across the four groups. Time to and duration of cytogenetic response were similar, as was progression-free survival (8% to 11% of patients experienced disease progression or died). Compared with the approved 70-mg twice-daily regimen, dasatinib 100 mg once daily resulted in significantly lower rates of pleural effusion (all grades, 7% v 16%; P = .024) and grade 3 to 4 thrombocytopenia (22% v 37%; P = .004), and fewer patients required dose interruption (51% v 68%), reduction (30% v 55%), or discontinuation (16% v 23%). Conclusion Dasatinib 100 mg once daily retains the efficacy of 70 mg twice daily with less toxicity. Intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events.

La renovación de la palabra en el bicentenario de la Argentina : los colores de la mirada lingüística

El libro reúne trabajos en los que se exponen resultados de investigaciones presentadas por investigadores de Argentina, Chile, Brasil, España, Italia y Alemania en el XII Congreso de la Sociedad Argentina de Lingüística (SAL), Bicentenario: la renovación de la palabra, realizado en Mendoza, Argentina, entre el 6 y el 9 de abril de 2010. Las temáticas abordadas en los 167 capítulos muestran las grandes líneas de investigación que se desarrollan fundamentalmente en nuestro país, pero también en los otros países mencionados arriba, y señalan además las áreas que recién se inician, con poca tradición en nuestro país y que deberían fomentarse. Los trabajos aquí publicados se enmarcan dentro de las siguientes disciplinas y/o campos de investigación: Fonología, Sintaxis, Semántica y Pragmática, Lingüística Cognitiva, Análisis del Discurso, Psicolingüística, Adquisición de la Lengua, Sociolingüística y Dialectología, Didáctica de la lengua, Lingüística Aplicada, Lingüística Computacional, Historia de la Lengua y la Lingüística, Lenguas Aborígenes, Filosofía del Lenguaje, Lexicología y Terminología.

Group photo, 1939

Group photo dated 1939. Back row left to right: Ma, Sally, Beverly. Front row, left to right: Alice, Jack Kevorkian, and Flora Kevorkian.

Group photo, 1939 (verso)

Verso of the 1939 group photo, with identifications.